Home › Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma
 

Keywords :   


Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma

2015-09-30 08:25:02| drugdiscoveryonline News Articles

Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer

Tags: germany cell drug announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
12.05Spate Unveils the Top Sustainability Trends Cycling Google Searches
12.05Oh K! is the Most Searched Beauty Brand in the World: Cosmetify
More »